KRASG12C Inhibitors vs Chemotherapy: Pooled Analysis from Two Phase 3 NSCLC Trials

A 2026 meta-analysis of two phase 3 randomized controlled trials (CodeBreaK 200 and KRYSTAL-12) involving 798 patients with KRASG12C-mutated non-small cell lung cancer. The dataset, authored by Shuang Liang and shared under a CC-BY-4.0 license, compares the efficacy and safety of KRASG12C inhibitors against conventional chemotherapy. It includes pooled results for progression-free survival, central nervous system progression, treatment response rates, and adverse events.

Use Cases

• Compare progression-free survival (PFS) and central nervous system-PFS (CNS-PFS) between treatment groups based on hazard ratios and survival rates.
• Analyze objective response rate (ORR) and disease control rate (DCR) differences between KRASG12C inhibitors and chemotherapy.
• Evaluate the safety profile of KRASG12C inhibitors based on treatment-related adverse event (TRAE) rates, including grade 3–5 events like diarrhea and elevated liver enzymes.
• Conduct subgroup analyses to assess the consistency of treatment benefits across different patient populations as mentioned in the description.

Strengths

• Data is derived from two phase 3 randomized controlled trials, a gold-standard study design for clinical evidence.
• Pooled analysis includes results from 798 patients, providing a substantial sample size for the comparison.
• Reports specific statistical outcomes, including hazard ratios (e.g., PFS HR: 0.62) and response rate ratios (e.g., ORR RR: 2.73).
• Includes detailed safety data, listing the top three grade 3–5 adverse events with precise percentages (e.g., diarrhea at 7.63%).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for certain analytical tasks.
• The dataset is very small (19.8 KB), indicating it likely contains summary-level results rather than individual patient-level data.

Provenance

Source

Author: Shuang Liang. Platform: figshare.

Collection Method

Systematic review and meta-analysis of published phase 3 randomized controlled trials (CodeBreaK 200 and KRYSTAL-12).

Freshness

Last updated 2026-04-15 05:47:44; freshness should be verified.